776 related articles for article (PubMed ID: 29055479)
1. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Fernández Ó
Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
[TBL] [Abstract][Full Text] [Related]
3. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Tramacere I; Del Giovane C; Salanti G; D'Amico R; Filippini G
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011381. PubMed ID: 26384035
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
7. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
8. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
[TBL] [Abstract][Full Text] [Related]
9. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
Noon KM; Montgomery SM; Adlard NE; Kroes MA
J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
[TBL] [Abstract][Full Text] [Related]
10. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
Montgomery SM; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
Piena MA; Heisen M; Wormhoudt LW; Wingerden JV; Frequin STFM; Uitdehaag BMJ
J Med Econ; 2018 Oct; 21(10):968-976. PubMed ID: 29911917
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
17. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
19. Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.
Fiander MDJ; Bhan V; Stewart SA; Parks NE
Can J Neurol Sci; 2019 Jul; 46(4):455-458. PubMed ID: 31113500
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S; Schmidt R; Straeten FA; Pul R; Kleinschnitz C; Wieshuber M; Lee DH; Linker RA; Doerck S; Straeten V; Windhagen S; Pawlitzki M; Aufenberg C; Lang M; Eienbroeker C; Tackenberg B; Limmroth V; Wildemann B; Haas J; Klotz L; Wiendl H; Ruck T; Meuth SG
J Neurol; 2019 Jan; 266(1):165-173. PubMed ID: 30446966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]